[Drug resistance of Mycobacteria tuberculosis in patients with new-onset pulmonary tuberculosis].
Statistics for the last 6 years show a trend to growing number of new cases with tuberculosis of the lungs with drug-resistant pathogen. In recurrent tuberculosis multiple drug resistance (MDR) was three times higher than in new cases. Treatment efficacy depended on MDR and patients' compliance. The results of the basic treatment course were unstable: many patients had exacerbation within 3-4 years after therapy, many patients died, especially those with M. tuberculosis resistant to many drugs.
T A
TA
Khudushina
E P
EP
Voloshina
N V
NV
Adamovich
M G
MG
Maslakova
N D
ND
Terekhova
D000904:Antibiotics, Antitubercular / Q000627:therapeutic use*; D000995:Antitubercular Agents / Q000627:therapeutic use*; D006801:Humans; D015994:Incidence; D007538:Isoniazid / Q000627:therapeutic use*; D009031:Moscow / Q000453:epidemiology; D009169:Mycobacterium tuberculosis / Q000187:drug effects / Q000302:isolation & purification / Q000472:pathogenicity; D012189:Retrospective Studies; D012293:Rifampin / Q000627:therapeutic use*; D013183:Sputum / Q000382:microbiology; D018088:Tuberculosis, Multidrug-Resistant / Q000175:diagnosis / Q000453:epidemiology*; D014397:Tuberculosis, Pulmonary / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology
D000904:Antibiotics, Antitubercular; D000995:Antitubercular Agents; D007538:Isoniazid; D012293:Rifampin